New data for Roche’s OCREVUS (ocrelizumab) show benefit in disability progression and cognitive decline in both secondary progressive and primary progressive multiple sclerosis April 4, 2022April 23, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Data up to 8-years for Roche’s OCREVUS (ocrelizumab)…Roche to present new OCREVUS (ocrelizumab) data in…Early treatment with Roche's OCREVUS leads to…Roche to present new data on OCREVUS in multiple…[Ad hoc announcement pursuant to Art. 53 LR] Roche…Roche's Kadcyla is the first targeted therapy…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
